Last reviewed · How we verify
KLH-2109 Placebo + Leurprorelin acetate
KLH-2109 Placebo + Leurprorelin acetate is a GnRH agonist Small molecule drug developed by JW Pharmaceutical. It is currently in Phase 3 development for Prostate cancer (hormone-sensitive), Endometriosis, Uterine fibroids. Also known as: KLH-2019 Placebo + Leurprorelin acetate Placebo.
Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.
Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Prostate cancer (hormone-sensitive), Endometriosis, Uterine fibroids.
At a glance
| Generic name | KLH-2109 Placebo + Leurprorelin acetate |
|---|---|
| Also known as | KLH-2019 Placebo + Leurprorelin acetate Placebo |
| Sponsor | JW Pharmaceutical |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Leuprorelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH) that initially stimulates the pituitary gland but with continuous exposure causes downregulation of GnRH receptors, resulting in sustained suppression of LH and FSH secretion. This leads to profound reduction in testosterone and estrogen levels. KLH-2109 appears to be a combination study with placebo control and leuprorelin acetate as the active comparator.
Approved indications
- Prostate cancer (hormone-sensitive)
- Endometriosis
- Uterine fibroids
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Headache
- Fatigue
Key clinical trials
- to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KLH-2109 Placebo + Leurprorelin acetate CI brief — competitive landscape report
- KLH-2109 Placebo + Leurprorelin acetate updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI
Frequently asked questions about KLH-2109 Placebo + Leurprorelin acetate
What is KLH-2109 Placebo + Leurprorelin acetate?
How does KLH-2109 Placebo + Leurprorelin acetate work?
What is KLH-2109 Placebo + Leurprorelin acetate used for?
Who makes KLH-2109 Placebo + Leurprorelin acetate?
Is KLH-2109 Placebo + Leurprorelin acetate also known as anything else?
What drug class is KLH-2109 Placebo + Leurprorelin acetate in?
What development phase is KLH-2109 Placebo + Leurprorelin acetate in?
What are the side effects of KLH-2109 Placebo + Leurprorelin acetate?
What does KLH-2109 Placebo + Leurprorelin acetate target?
Related
- Drug class: All GnRH agonist drugs
- Target: All drugs targeting GnRH receptor
- Manufacturer: JW Pharmaceutical — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Prostate cancer (hormone-sensitive)
- Indication: Drugs for Endometriosis
- Indication: Drugs for Uterine fibroids
- Also known as: KLH-2019 Placebo + Leurprorelin acetate Placebo
- Compare: KLH-2109 Placebo + Leurprorelin acetate vs similar drugs
- Pricing: KLH-2109 Placebo + Leurprorelin acetate cost, discount & access